Letter to the EditorDuration of immunosuppressive therapy in autoimmune hepatitis
References (5)
- et al.
Prognosis of histological cirrhosis in type 1 autoimmune hepatitis
Gastroenterology
(1996) - et al.
Clinical and prognostic implications of HLA B8 in corticosteroid-treated severe autoimmune chronic active hepatitis
Gastroenterology
(1990)
There are more references available in the full text version of this article.
Cited by (105)
Long-term Outcome of Autoimmune Hepatitis: Consecutive Patient Cohort and Data on the Second Twenty Years
2023, Digestive and Liver DiseaseSupport of precision medicine through risk-stratification in autoimmune liver diseases – histology, scoring systems, and non-invasive markers
2018, Autoimmunity ReviewsCitation Excerpt :The combination therapy seemed promising in improving treatment response, but a small number of patients in the series described hampered clear conclusions. American and European guidelines agree that treatment should be carried on for at least 2–3 years and any trial of complete withdrawal of drugs should be postponed until at least 2 years of biochemical remission [7, 97], even though it has been suggested a more prolonged interval of time might be needed [128]. This careful approach derives from the knowledge that exacerbation in disease activity after treatment withdrawal (known as Relapse or Flare) is very common in patients with AIH (50–90% of patients) and represent a major concern [129–132].
Autoimmune hepatitis in the pediatric age
2017, Boletin Medico del Hospital Infantil de MexicoEASL clinical practice guidelines: Autoimmune hepatitis
2015, Journal of HepatologyDiagnosis and management of autoimmune hepatitis
2015, Clinics in Liver Disease
Copyright © 2001 European Association for the Study of the Liver. Published by Elsevier Ireland Ltd. All rights reserved.